Business
IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform
IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs).Yesterday, at the
About this update from In8bio, Inc.
[{"type":"text","content":"IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs).Yesterday, at the American Society for Gene & Cell Therapy (ASGCT) 25th Annual Meeting, IN8bio announced data on its iPSC platform showing that our iPSC-derived gamma-delta T cells demonstrated robust cytotoxicity and can be genetically modified with an internally developed chimeric antigen receptor (CAR-T) construct.With these data, IN8bio extends its leadership in the gamma-delta T cell space as the first to demonstrate the directed iPSC differentiation of both Vdelta1 (Vd1+) and Vdelta2 (Vd2+) gamma-delta sub-types.IN8bio will hold a webcast R&D Workshop on May 17, 2022 at 6:00 p.m. EDT to discuss the new platform. Speakers include Dieter Kabelitz, M.D., from the University of Kiel and Bruce Levine, Ph.D., from the University of Pennsylvania. NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today announced data emerging from the Company’s recently unveiled iPSC-based gamma-delta T cell platform. iPSCs represent a significant step toward next generation approaches of cellular manufacturing for true allogeneic ‘off-the-shelf’ innate cell therapies, and further broaden the Company’s capabilities around the expansion and genetic engineering of gamma-delta T cells. “Our iPSC program is innovative and could provide a potentially unlimited ‘off-the-shelf’ source of gamma-delta T cells,” said Lawrence Lamb Ph.D., CSO, and co-founder of IN8bio. “This provides another tool to advance IN8bio’s gamma-delta T cell-based approaches to target cancer. Our team has achieved a number of firsts and are advancing iPSCs as an approach to Vd1+ based gamma-delta T cell therapies in addition to our ongoing work with Vd2+ cells. Our team continues to lead in the development of gamma-delta T cell therapies as we work towards transforming hope into reality for cancer patients.” IN8bio presented data from the iPSC platform during both podium and poster presentations at the ASGCT 25th Annual Meeting in Washington, DC, on May 16, 2022. These data demonstrated that donor cells could be programmed into iPSCs, expanded, then differentiated in a stepwise feeder-free process into gamma...